Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

Phase 4 Completed 384 enrolled Regionshospitalet Viborg, Skive

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles

Timeline

Start: 2009-01
Primary completion: 2011-12
Completion: 2011-12

Publications

Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013 Sep;28(9):2511-21. doi: 10.1093/humrep/det249. Epub 2013 Jun 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	buserelin	Unknown	0.5 mg	Subcutaneous
Comparator	human chorionic gonadotropin	Protein / enzyme biologic	1500 iu	Subcutaneous
Comparator	human chorionic gonadotropin	Protein / enzyme biologic	5000 iu	Subcutaneous

Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

Summary

Timeline

Publications

Drugs

Indications